Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Isotechnika -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (84)	6/18/2003 6:15:56 PM
From: Icebrg	Read Replies (1) \| Respond to of 285

Pfizer (evidently) has a drug under development that looks like a potential competitor to ISA247. The following comments were made by S G Cowen as a follow-up to Pfizer's recent analysts' meeting. CP-690,550 (Transplant Rejection) PFE is developing CP-690,550, an oral janus kinase 3 (JAK-3) inhibitor, for the prevention of transplant rejection. Phase I studies and primate renal transplantation studies have commenced. Early data suggest that CP-690,550 is associated with a longer transplant survival duration compared to currently marketed transplant drugs. CP-690,550 is well tolerated in humans. PFE has an investigational program in psoriasis. We have no sales contribution for CP-690,550 in our model.